Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced Dyno-yp2, a novel adeno-associated ...
Building on the development of a suite of best-in-class capsids for retinal gene therapy, Avista has launched ARTEMIS, a powerful AI platform for capsid engineering. ARTEMIS leverages large, ...
PHILADELPHIA, PA — Latus Bio, Inc. has unveiled groundbreaking research on a novel adeno-associated virus (AAV) capsid variant, AAV-Ep+, which shows significant promise for advancing gene therapy ...
Adeno-associated virus (AAV) preparations remain highly heterogeneous through upstream and downstream bioprocessing phases. Characterizing empty, partial, full, overfilled capsids and encapsulated ...
RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted 20 ...
Let us help you with your inquiries, brochures and pricing requirements Request A Quote Download PDF Copy Download Brochure Accurate viral vector characterization in ...
"CMRI has pioneered the work of establishing barcoded AAV capsid kits, which allow for NGS-based parallel evaluation of large numbers of AAVs for their performance at both DNA (proxy for cell entry) ...
Together with the existing Vericheck ddPCR Empty-Full Capsid Kits for serotypes AAV5 and AAV9, the addition of the new kits for serotypes AAV2 and AAV8 extends the range’s suitability to approximately ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback